Replies to post #94461 on Biotech Values

[poorgradstudent]

benefit of a big name partner seem to be muted by the deal terms involving ARRY paying up for some development costs

I guess it depends on what the actual split and burden are, but note that this is what has put ARIA into an unfortunate predicament.

The weaker financial status of most startups, combined with the relatively thorough approach of big pharma towards trials can tax the balance sheet.

[turtlepower]

ARRY's development responsibilities are as follows

"Under the Agreement, Array is responsible for completing the on-going Phase 1 clinical trial of ARRY-162 and the further development of ARRY-162 for up to two indications. Novartis is responsible for all other development activities. Novartis is also responsible for the commercialization of products under the Agreement, subject to Array's option to co-detail approved drugs in the United States. "